Validation of a health-related quality of life instrument for primary ciliary dyskinesia (QOL-PCD)

Thorax

Volumn 72, Issue 9, 2017, Pages 832-839

  Behan, Laura ^a,b,c   Leigh, Margaret W ^d   Dell, Sharon D ^e,f   Dunn Galvin, Audrey ^c   Quittner, Alexandra L ^g   Lucas, Jane S ^a,b  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c UNIVERSITY COLLEGE CORK   (Ireland)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g Department of Biology   (United States)

Author keywords

Psychology; Rare lung diseases; Respiratory Measurement

Indexed keywords

ADULT; AGE; AGED; ARTICLE; CILIARY DYSKINESIA; EMOTION; EMPLOYMENT STATUS; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH BELIEF; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSYCHOMETRY; QUALITY OF LIFE ASSESSMENT; REPRODUCIBILITY; SHORT FORM 36; SOCIAL INTERACTION; VALIDATION STUDY; ADOLESCENT; AGE DISTRIBUTION; CLINICAL TRIAL; COMPLICATION; EMPLOYMENT; KARTAGENER SYNDROME; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGY; QUALITY OF LIFE; QUESTIONNAIRE; RESPIRATORY TRACT DISEASES; SEX RATIO; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; EMPLOYMENT; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; KARTAGENER SYNDROME; MALE; MIDDLE AGED; PSYCHOMETRICS; QUALITY OF LIFE; REPRODUCIBILITY OF RESULTS; RESPIRATORY TRACT DISEASES; SEX DISTRIBUTION; SURVEYS AND QUESTIONNAIRES; YOUNG ADULT;

EID: 85020514939     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2016-209356     Document Type: Article

References (35)

1. Mullowney T, Manson D, Kim R, et al. Primary ciliary dyskinesia and neonatal respiratory distress. Pediatrics 2014;134:1160-6.
2. Behan L, Dimitrov BD, Kuehni CE, et al. PICADAR: A diagnostic predictive tool for primary ciliary dyskinesia. Eur Respir J 2016;47:1103-12.
3. Maglione M, Bush A, Montella S, et al. Progression of lung disease in primary ciliary dyskinesia: is spirometry less accurate than CT? PediatrPulmonol 2012;47:498-504.
4. Marthin JK, Petersen N, Skovgaard LT, et al. Lung function in patients with primary ciliary dyskinesia: A cross-sectional and 3-decade longitudinal study. Am J Respir Crit Care Med 2010;181:1262-8.
5. Noone PG, Leigh MW, Sannuti A, et al. Primary ciliary dyskinesia: diagnostic and phenotypic features. Am J Respir Crit Care Med 2004;169:459-67.
6. Shapiro AJ, Davis SD, Ferkol T, et al. Laterality defects other than situs inversus totalis in primary ciliary dyskinesia: insights into situs ambiguus and heterotaxy. Chest 2014;146:1176-86.
7. Magnin ML, Cros P, Beydon N, et al. Longitudinal lung function and structural changes in children with primary ciliary dyskinesia. PediatrPulmonol 2012;47:816-25.
8. Montella S, Maglione M, Bruzzese D, et al. Magnetic resonance imaging is an accurate and reliable method to evaluate non-cystic fibrosis paediatric lung disease. Respirology 2012;17:87-91.
9. Green K, Buchvald FF, Marthin JK, et al. Ventilation inhomogeneity in children with primary ciliary dyskinesia. Thorax 2012;67:49-53.
10. Irving SJ, Ives A, Davies G, et al. Lung clearance index and high-resolution computed tomography scores in primary ciliary dyskinesia. Am J Respir Crit Care Med 2013;188:545-9.
11. Boon M, Vermeulen FL, Gysemans W, et al. Lung structure-function correlation in patients with primary ciliary dyskinesia. Thorax 2015;70:339-45.
12. Nyilas S, Schlegtendal A, Yammine S, et al. Further evidence for an association between LCI and FEV1 in patients with PCD. Thorax 2015;70:896.
13. Apolone G, De Carli G, Brunetti M, et al. Health-related quality of life (HR-QOL) and regulatory issues. An assessment of the European Agency for the Evaluation of Medicinal Products (EMEA) recommendations on the use of HR-QOL measures in drug approval. Pharmacoeconomics 2001;19:187-95.
14. European Medicines Agency; Committee for Medicinal Products for Human Use (CMHP). Reflection paper on the regulatory guidance for the use of health related quality of life (HRQL) measures in the evaluation of medicinal products. 2005.http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general-content-001238.jspamp;mid=WC0b01ac0580032ec4 (accessed 21 Feb 2017).
15. US Department of Health and Human Services; Food and Drug Administration. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labelling claims. Dec 2009. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf (accessed 21 Feb 2017).
16. Barbato A, Frischer T, Kuehni CE, et al. Primary ciliary dyskinesia: A consensus statement on diagnostic and treatment approaches in children. Eur Respir J 2009;34:1264-76.
17. Lucas JS, Carroll M. Primary ciliary dyskinesia and cystic fibrosis: different diseases require different treatment. Chest 2014;145:674-6.
18. Quittner AL, Modi A, Cruz I. Systematic review of health-related quality of life measures for children with respiratory conditions. Paediatr Respir Rev 2008;9:220-32.
19. Lucas JS, Behan L, Dunn Galvin A, et al. A quality-of-life measure for adults with primary ciliary dyskinesia: QOL-PCD. Eur Respir J 2015;46:375-83.
20. Lucas JS, Burgess A, Mitchison HM, et al. Diagnosis and management of primary ciliary dyskinesia. Arch Dis Child 2014;99:850-6.
21. Lucas JS, Chetcuti P, Copeland F, et al. Overcoming challenges in the management of primary ciliary dyskinesia: The UK model. Paediatr Respir Rev 2014;15:142-5.
22. Bonett DG. Sample size requirements for testing and estimating coefficient alpha. J Educ Behav Stat 2002;27:335-40.
23. Hays RD, Hayashi T. Beyond internal consistency reliability: rationale and users guide for multitrait analysis program on the microcomputer. Behav Res Methods Instrum Comput 1990;22:167-75.
24. Campbell DT, Fiske DW. Convergent and discriminant validation by the multitrait-multimethod matrix. Psychol Bull 1959;56:81.
25. Hays RD, Anderson R, Revicki D. Psychometric considerations in evaluating health-related quality of life measures. Qual Life Res 1993;2:441-9.
26. Terwee CB, Bot SDM, de Boer MR, et al. Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol 2007;60:34-42.
27. Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika 1951;16:297-334.
28. Hays RD, Revicki D. Reliability and validity (including responsiveness). Assessing Qual Life Clin Trials 2005;2:25-39.
29. Cohen J. Statistical power analysis for the behavioral sciences. Hillsdale, NJ: Lawrence Erlbaum Associates, 1988.
30. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989;10: 407-15.
31. Cella D, Eton DT, Lai JS, et al. Combining anchor and distribution-based methods to derive minimal clinically important differences on the functional assessment of cancer therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 2002;24:547-61.
32. Wyrwich KW, Tierney WM, Wolinsky FD. Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol 1999;52:861-73.
33. Chen WH, Lenderking W, Jin Y, et al. Is Rasch model analysis applicable in small sample size pilot studies for assessing item characteristics? An example using PROMIS pain behavior item bank data. Qual Life Res 2014;23: 485-93.
34. McManus IC, Mitchison HM, Chung EMK, et al. Primary ciliary dyskinesia (Siewerts/Kartageners syndrome): respiratory symptoms and psycho-social impact. BMC Pulm Med 2003;3:4.
35. Kobbernagel HE, Buchvald FF, Haarman EG, et al. Study protocol, rationale and recruitment in a European multi-centre randomized controlled trial to determine the efficacy and safety of azithromycin maintenance therapy for 6 months in primary ciliary dyskinesia. BMC Pulm Med 2016;16:104.